ESC Premium Access

Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk

logo

Congress Presentation

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
50 presentations
3 followers

3 more presentations in this session

New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes

Speaker: Doctor M. Kosiborod (Kansas City, US)

Thumbnail

Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction

Speaker: Doctor B. Scirica (Boston, US)

Thumbnail

Connecting with the speakers: Questions and Answers

Speaker: Doctor M. Kosiborod (Kansas City, US) Professor J. Deanfield (London, GB) Doctor B. Scirica (Boston, US)

Thumbnail

Access the full session

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Speakers: Professor J. Deanfield, Doctor M. Kosiborod, Doctor B. Scirica, Doctor M. Kosiborod, Professor J. Deanfield...
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb